Peptidome Analysis of Cerebrospinal Fluid by LC-MALDI MS

Mikko Hölttä1, Henrik Zetterberg1, Ekaterina Mirgorodskaya2, Niklas Mattsson1, Kaj Blennow1, Johan Gobom1*

1 Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, 2 Department of Occupational and Environmental Medicine, The Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden

Abstract

We report on the analysis of endogenous peptides in cerebrospinal fluid (CSF) by mass spectrometry. A method was developed for preparation of peptide extracts from CSF. Analysis of the extracts by offline LC-MALDI MS resulted in the detection of 3,000–4,000 peptide-like features. Out of these, 730 peptides were identified by MS/MS. The majority of these peptides have not been previously reported in CSF. The identified peptides were found to originate from 104 proteins, of which several have been reported to be involved in different disorders of the central nervous system. These results support the notion that CSF peptidomics may be viable complement to proteomics in the search of biomarkers of CNS disorders.

Introduction

For diseases of the central nervous system (CNS), cerebrospinal fluid (CSF) is a valuable source of biomarkers that can aid in diagnosis, provide clues to disease mechanisms and facilitate development of novel therapies. Generated through filtration of blood in the choroid plexus and by diffusion from the extracellular matrix of the brain into the ventricles [1], the CSF surrounds the brain and the spinal cord. Being in direct contact with the brain, many brain proteins diffuse into the CSF; approximately 20% of the proteins in CSF are estimated to be brain-derived [2]. CSF is produced at a rate of 500 ml/day and turns over approximately 4 times per day by drainage into the blood [3]. Thus, many ongoing processes in the CNS are reflected in the molecular composition of the CSF. Several CSF biomarkers have already been identified for various diseases and are used in research, clinical trials and clinical practice, including CSF-specific IgG immunoglobulins in multiple sclerosis, the 14-3-3 protein in Creutzfeld-Jakob’s disease (CJD), the tau protein, and the β-amyloid peptides in Alzheimer’s disease (AD).

While several proteomic studies have expanded our knowledge of the CSF protein composition [1,2], there are comparatively few reports on the CSF peptidome. A few recent studies have identified a large number of endogenous peptides in the CSF [14–17]. Several truncated forms of these peptides and the proteins they derive from are involved in diverse biological processes, e.g., degeneration/regeneration, neuronal damage, growth, development, and learning [2]. Others may reflect the proteolytic activity in the CNS that leads to their formation through metabolic processing [16]. Studies have shown that peptide patterns can discriminate between different forms of cancer in serum [18–20] and discriminate AD patients from controls in both serum and CSF [21,22].

Compared to CSF proteomics, the pursuit of the CSF peptidome is also motivated for analytical reasons. The CSF protein composition spans a concentration range of over ten orders of magnitude and is dominated by a small number of highly abundant proteins, most notably albumin, which accounts for over 60% of the total protein content [23–25]. Compared to albumin, for example, the concentration of the tau protein, a marker of neuronal degradation, is a million-fold lower. Global proteomic workflows generally have a strong bias towards detecting proteins of high abundance. The reasons for this are both the dynamic range of the mass spectrometric instrumentation, as well as the limited loading capacity of the separation techniques used upstream of the mass spectrometer. This requires the use of extensive sample prefractionation and sample enrichment for the detection and identification of low abundant proteins. The complexity of such workflows results in long analysis times and often compromises the analytical reproducibility, thereby hampering their use in clinical proteomic studies, in which comparative analysis of large sample sets are required. The peptides in CSF, in contrast, can be isolated relatively easily. Yuan et al demonstrated that ultrafiltration is an effective method for isolating the low molecular weight fraction (<5 kDa) of the human lumbar CSF proteome [17]. Using this strategy, Zouzman et al analyzed the CSF peptidome and proteome in depth, and found 563 endogenous peptides originating from 91 proteins [14].

Here we employed nano-LC coupled to off-line to matrix-assisted laser desorption/ionization (MALDI) MS for analyzing
CSF peptides in the mass range 700–5,000 Da. A method based on ultrafiltration for preparation of peptide extracts from CSF was optimized. This workflow is aimed to be suitable for comparative analysis of large clinical sample sets, necessitating a fast and simple sample preparation.

**Results and Discussion**

**Sample preparation**

The CSF peptidome constitutes only a minor fraction of the total protein contents of CSF. Several known bioactive peptides are present at concentrations in the pg/ml range, requiring the analysis of a few hundred microlites of CSF to detect them by mass spectrometry. Because of the limited loading capacity of nano-LC columns (<1 µg), it is necessary to enrich the peptide fraction. Ultrafiltration using molecular weight cut-off (MWCO) filters provides a simple means to achieve this. Filters of different cut-off sizes (10 kDa, 30 kDa, 50 kDa) were evaluated. 50 kDa filters resulted in permeability of significant amounts of albumin (data not shown). While 10 kDa filters efficiently removed albumin, they retained a large part of the peptides in the mass range of interest (data not shown). According to the product documentation for the filters the recovery of a peptide of 1,350 Da is only approximately 76%. 30 kDa filters were found optimal for our application, achieving efficient removal of albumin, the most abundant CSF protein, without compromising peptide recovery.

From studies in plasma and CSF it is well known that many peptides bind to larger proteins and may therefore be retained in the ultrafiltration step [15,26–28]. To improve the recovery of such peptides we investigated the effect of pretreating CSF samples with different concentrations of acetonitrile (ACN) and formic acid (FA), in order to dissociate the peptides from the carrier proteins prior to the ultrafiltration step. A CSF pool was divided into several 500 µl aliquots to which ACN or FA were added at different concentrations as described in the method section. The filtrates were analyzed by LC-MALDI MS and evaluated on the basis of number of detected compounds. Without any sample pretreatment, 2,445 compounds were detected (Figure 1 a). In a CSF sample treated with 20% ACN, the number of detected compounds increased to 3,543 (Figure 1 b). When the concentration of ACN was increased to 40% the amount of peptides in the flow through dropped significantly. A possible explanation for the observed decrease is that at this high ACN concentration, a large part of the sample proteins precipitate, resulting in co-precipitation of peptides. The highest numbers of compounds were detected when the CSF was incubated with 20% ACN. Addition of FA up to 5% to the samples also increased the number of detected compounds, however less than ACN. Increasing the FA concentration to 10% did not yield any additional improvement. Combining ACN and FA yielded poor results.

**Peptide identification**

Identification of endogenous peptides by sequence database searching is more challenging than identification of proteins in tryptic digests. Because the peptides are not produced by cleavage by one specific protease, restrictions regarding enzyme cleavage specificity cannot be applied in the database search, increasing the number of peptide sequences to consider in the search by a factor of 100–1,000, and thereby decreasing the significance of the matches in the database searches. Performing a database search with Mascot and filtering for a false discovery rate (FDR) of 1% (corresponding to a Mascot MOWSE score of 41 in the search) resulted in 596 peptide identifications. However, upon inspection of peptide hits with lower scores it was found that several of these could be confirmed based on the characteristic fragment ions arising from the presence of specific amino acids and the location of charged residues in the amino acid sequence. For singly charged peptide ions, strong charge-remote fragmentation C-terminally to aspartic acid and, to somewhat lesser degree, glutamic acid for peptides containing arginine, produces characteristic b- or y-fragment ions, depending on the location of the arginine [29,30]. Prominent cleavage N-terminally to proline residues also produces strong b- or y-ions. Peptides that display these fragmentation characteristics often score poorly in database searches due to their selective fragmentation. However, these diagnostic fragment ions provide means to manually evaluate peptide specific matches retrieved by database searches.

For peptide identification, manual validation was performed on all database search results retrieved using a relatively low score threshold: ion score >15 and at least one peptide per protein with ion score >27. With these settings, a total of 4,185 peptide matches were retrieved. Manual validation was based primarily on the fragmentation rules discussed above for peptides containing aspartic acid/glutamic acid and arginine, and peptides containing proline. Upon inspection of the raw spectra, errors in the automatic peak detection were corrected, sometimes increasing the number of assigned peaks. In some cases validation was supported by similarity of the fragment ion pattern with that of an already identified peptide, covering partly the same amino acid sequence.

Figure 2 shows two examples illustrating the application of the described validation criteria for a strong and a weak peptide match. The fragment ion spectrum of m/z 3511.7738 (Figure 2 a) matched the peptide SVNYPYLQQRDLNVKAKSVPHFSDEDKDFE from Neuroendocrine protein 7B2 with an ion score of 194.9. Charge-remote fragmentation C-terminally to Asp-12, Asp-23, Asp-27, Asp-29 and Asp-29 due to the presence of arginine at the N-terminal part of the peptide (Arg-10) results in abundant corresponding b-ions, confirming the assignment of the peptide. The lowest scoring peptide match which was validated was the peptide KANDESNHSVDIQPSLEKVSREFH (m/z 3900.3891) derived from Osteopontin, which received an ion score of 15.8. Prominent charge-remote fragmentation is observed C-terminally to Asp-14, Asp-11, Glu-8 (y-18), Glu-17 (y-9), in this case giving rise to the corresponding strong y-ions, y12, y15, y18, and y9, respectively, due to the presence of Arg-23 near the C-terminus of the peptide. Despite that the spectrum in the latter example only contains a few fragment ion signals the predictability of the fragment ion peak pattern based on the matched peptide sequence provides evidence for the correctness of the identification.

A histogram of the number of manually validated and rejected peptide matches as a function of ion score (Figure 3) shows that quite a large number of peptide hits with low ion score could be validated. A total of 730 peptide matches were validated. The 22% increase of assigned peptides by manual evaluation compared to the 596 peptides identified with an FDR of 1% in the Mascot database search is significant and suggests that, particularly for the analysis of singly-charged ions, search algorithms may be improved by implementing amino acid- and charge-based fragmentation schemes in their scoring algorithms.

The identified peptides are listed in Table S1. The identifications comprised 626 unique peptide sequences (not taking into account post-translational modifications) originating from 104 proteins (Table 1). The mass spectrometric data is available via the PRoteomics IDEntifications database [31] (PRIDE, http://www.ebi.ac.uk/pride/, Accession number 24353).

---

---

---
Figure 1. LC-MS profiles of CSF peptides. The LC retention time is shown on the y-axis and the m/z on the x-axis. (a) Without sample pretreatment, 2,445 compounds were detected. (b) When adding 20% ACN prior to the ultrafiltration step, the number increased to 3,543.

doi:10.1371/journal.pone.0042555.g001

Figure 2. Peptide identification. (a) MS/MS spectrum of an ion of m/z 3511.7738 matching the peptide SVNPYLQGQRLDNVAKKSVPHFSDEDKDPE from Neuroendocrine protein 7B2 with an ion score of 192.4. Charge-remote fragmentation C-terminally to Asp-12, Asp-25, Asp-27, and Asp-29 due to the presence of arginine at the N-terminal part of the peptide (Arg-10), results strong corresponding b-ions. (b) MS/MS spectrum of an ion of m/z 3000.3891 matching the peptide KANDESNEHDVIDSQELSKVSREFH with an ion score of 15.8. Charge-remote fragmentation is observed C-terminally to Asp-14, Asp-11, Glu-8 (y-18), Glu-17 (y-9), in this case giving rise to the corresponding strong y-ions, y12, y15, y18, and y9, respectively, due to the presence of Arg-23 near the C-terminus of the peptide.

doi:10.1371/journal.pone.0042555.g002
Comparisons with other studies

Comparing the peptides identified in our study to those identified in the study by Zougman et al. [14], one of the most comprehensive CSF peptidomic studies to date, showed that only 23% of the peptides identified in our study were present in the other data set (Figure 4 a). The large difference between the data sets may be attributed to the different ionization techniques used in the two studies (MALDI vs. ESI), to differences in the method used for preparation of the peptide extracts, and that different CSF samples were analyzed.

To assess how the CSF peptidome compares to the CSF proteome, we compared the proteins represented by the endogenous peptides identified in the current study and in the study by Zougman et al. with the extensive CSF proteomic analysis by Schutzer et al. comprising 2,462 proteins [7] (Figure 4 b). Both peptidomic data sets have high overlap with the proteomic set. Thus, on a protein level, the peptidomic approaches used in the two studies mainly identifies peptides derived from the same proteins that are found by global proteomic analyses.

Biological functions of the identified proteins

While the significance of the endogenous peptides in CSF is still largely unknown, several of the precursor proteins from which they derive are associated with various brain disorders and known cellular processes in the brain. A few examples are given below. While the presence in CSF of all of these proteins has been reported previously [7], several of the endogenous peptides derived from these proteins are reported for the first time.

**Amyloid beta peptides.** The amyloid beta A4 protein (amyloid precursor protein, APP) plays a central role in the pathophysiological processes in AD, which is characterized by progrediating neuronal degeneration with amyloid deposits [32]. By enzymatic processing of APP, the peptide amyloid beta (Aβ)1–42 is generated which is highly prone to aggregation and is the major constituent of the amyloid plaques that form in the brain. Aβ1–42 is also used as a CSF biomarker for AD [33]. In this study, we detected Aβ1–14, 1–15, 1–16, 1–17, 1–19, and 5–15 (Figure 5 a). The existence of several of these fragments have been recently reported in CSF in a study using immunoprecipitation in combination with mass spectrometry [34]. The C-termini of these fragments span the α-secretase cleavage site and may thus be markers of non amyloidogenic APP processing that may be protective from AD [35]. The identification of Aβ5–15 is the first report of this truncated form in CSF. The identification of Aβ peptides starting at position 5 is especially interesting since such peptides may represent the activity of an APP processing pathway that is up-regulated after inhibition of the major Aβ producing enzyme BACE1 [36,37] and CSF Aβ5-X peptides may be useful as pharmacodynamic markers in trials of BACE1-inhibitors [38].

**APLP1.** CSF also contains several amyloid-like proteins, which have sequence homology to APP, and that to some extent undergo similar processing. One such protein is the amyloid precursor-like protein 1 (APLP1). APLP1 undergoes processing by BACE and γ-secretase generating Aβ-like peptides of which one has been shown to have potential value as a biomarker for AD [39]. Several of these Aβ-like peptides were also identified in our

---

**Figure 3. Stacked histogram of all peptide matches as a function of ion score.** Peptide matches were retrieved that fulfilled the criteria: ion score >15 and at least one peptide match with ion score >27 per protein. The coloured segments indicate the number of validated (green) and rejected (red) peptide matches.

doi:10.1371/journal.pone.0042555.g003
Table 1. List of identified proteins from the analysis of the CSF peptidome using LC-MALDI MS/MS.

| Entry name   | Protein name                                                                 |
|--------------|-----------------------------------------------------------------------------|
| PTPRR_HUMAN  | Receptor-type tyrosine-protein phosphatase R isoform 1 precursor            |
| NBL1_HUMAN   | Neuroblastoma suppressor of tumorigenicity 1 isoform 1                      |
| PLM_HUMAN    | Phospholemman precursor                                                     |
| CADH2_HUMAN  | Cadherin-2 preproprotein                                                   |
| THR_HUMAN    | Prothrombin preproprotein                                                   |
| A4_HUMAN     | Amyloid beta A4 protein isoform h precursor                                 |
| ADML_HUMAN   | ADM precursor                                                               |
| TICN3_HUMAN  | Testican-3 isoform 1                                                        |
| VTNC_HUMAN   | Vitronectin precursor                                                       |
| CXL16_HUMAN  | C-X-C motif chemokine 1                                                     |
| 7B2_HUMAN    | Neuroendocrine protein 7B2 isoform 2                                        |
| OSTP_HUMAN   | Osteopontin-D                                                               |
| CSTN1_HUMAN  | Calsyntenin-1 isoform 2                                                     |
| TTHY_HUMAN   | Transthyretin precursor                                                     |
| SODC_HUMAN   | Superoxide dismutase [Cu-Zn]                                                |
| SORC2_HUMAN  | VPS10 domain-containing receptor SorCS2 precursor                           |
| CD99_HUMAN   | CD99 type II                                                                |
| FIBB_HUMAN   | Fibrinogen beta chain isoform 1 preproprotein                              |
| CO3_HUMAN    | Complement C3 precursor                                                     |
| TYB10_HUMAN  | Thymosin beta-10                                                            |
| FIBG_HUMAN   | Fibrinogen gamma chain isoform gamma-A precursor                            |
| PGCB_HUMAN   | Brevican core protein isoform 1                                             |
| SAA_A_HUMAN  | Putative serum amyloid A-3 protein                                           |
| APLP2_HUMAN  | Amyloid-like protein 2 isoform 4 precursor                                  |
| TENR_HUMAN   | Isoform 2 of Tenascin-R                                                      |
| AACT_HUMAN   | Isoform 3 of Alpha-1-antichymotrypsin                                       |
| FXYD6_HUMAN  | FXYD domain-containing ion transport regulator 6 precursor                 |
| SCG1_HUMAN   | Secretogranin-1 precursor                                                   |
| COIA1_HUMAN  | Isoform 3 of Collagen alpha-1(XVIII) chain                                  |
| ANGL2_HUMAN  | Angiopoietin-related protein 2 precursor                                    |
| DKK3_HUMAN   | Dickkopf-related protein 3 precursor                                         |
| C91L2_HUMAN  | CD99 antigen-like protein 2 isoform 3 precursor                             |
| CAD19_HUMAN  | Cadherin-19 preproprotein                                                   |
| FBLN3_HUMAN  | Isoform 4 of EGF-containing fibulin-like extracellular matrix protein 1     |
| SE6L1_HUMAN  | Seizure 6-like protein isoform 2 precursor                                  |
| ANFC_HUMAN   | C-type natriuretic peptide precursor                                        |
| AUGN_HUMAN   | Augurin precursor                                                           |
| NPTXR_HUMAN  | Neuronal pentraxin receptor                                                  |
| TRH_HUMAN    | Prothyroliberin precursor                                                   |
| PCSK1_HUMAN  | ProSAAS precursor                                                           |
| SFRP4_HUMAN  | Secreted frizzled-related protein 4 precursor                               |
| ITIHS_HUMAN  | LLLL311                                                                    |
| FMOD_HUMAN   | Fibromodulin precursor                                                      |
| MIME_HUMAN   | Mimecan preproprotein                                                       |
| SPR1_HUMAN   | SPARC-like protein 1                                                         |
| ECM1_HUMAN   | Extracellular matrix protein 1 isoform 3 precursor                           |
| CART_HUMAN   | Cocaine- and amphetamine-regulated transcript protein                       |
| APOL_HUMAN   | Apolipoprotein E precursor                                                  |
| NSG1_HUMAN   | Neuron-specific protein family member                                       |
Table 1. Cont.

| Entry name   | Protein name                                                                 |
|--------------|------------------------------------------------------------------------------|
| PRIO_HUMAN   | Isoform 2 of Major prion protein                                             |
| GELS_HUMAN   | Gelsolin isoform a precursor                                                 |
| PTGDS_HUMAN  | Prostaglandin-H2 D-isomerase                                                  |
| PTTPRZ_HUMAN | Isoform Short of Receptor-type tyrosine-protein phosphatase zeta              |
| A2AP_HUMAN   | Alpha-2-antiplasmin isoform a precursor                                      |
| P3IP1_HUMAN  | HGFL(S) protein                                                              |
| CADM3_HUMAN  | Isoform 3 of Cell adhesion molecule 3                                        |
| SCG2_HUMAN   | Secretogranin-2 precursor                                                    |
| IBPS_HUMAN   | Insulin-like growth factor-binding protein 5 precursor                       |
| A1ATR_HUMAN  | Putative alpha-1-antitrypsin-related protein                                 |
| GP158_HUMAN  | Probable G-protein coupled receptor 158 precursor                            |
| SCG3_HUMAN   | Secretogranin-3 isoform 1 precursor                                          |
| FIBA_HUMAN   | Fibrinogen alpha chain isoform alpha preproprotein                           |
| GPR37_HUMAN  | Probable G-protein coupled receptor 37 precursor                             |
| CSF1_HUMAN   | Macrophage colony-stimulating factor 1                                       |
| TICN1_HUMAN  | Testican-1 precursor                                                         |
| SFRP3_HUMAN  | Secreted frizzled-related protein 3 precursor                                |
| CMGA_HUMAN   | Chromogranin-A preproprotein                                                 |
| NCKO2_HUMAN  | Sodium/potassium/calcium exchanger 2 isoform 2                               |
| ITA7_HUMAN   | Isoform Alpha-7X2DB of Integrin alpha-7                                      |
| RNAS1_HUMAN  | Ribonuclease pancreatic precursor                                            |
| A1AT_HUMAN   | Isoform 3 of Alpha-1-antitrypsin                                             |
| PENK_HUMAN   | Proenkephalin-A preproprotein                                                |
| SMS_HUMAN    | Somatostatin preproprotein                                                   |
| CO4A_HUMAN   | Complement C4-A                                                              |
| IGF2_HUMAN   | Isoform 2 of Insulin-like growth factor II                                   |
| APLP1_HUMAN  | Amyloid-like protein 1 isoform 1 precursor                                   |
| PTTPR2_HUMAN | Isoform 3 of Receptor-type tyrosine-protein phosphatase N2                   |
| TKNN_HUMAN   | Tachykinin-3 isoform 2 preproprotein                                         |
| MOG_HUMAN    | Isoform 9 of Myelin-oligodendrocyte glycoprotein                             |
| CYTC_HUMAN   | Cystatin-C preproprotein                                                     |
| CLUS_HUMAN   | Isoform 5 of Clusterin                                                       |
| PCDG3_HUMAN  | Protocadherin gamma-A3 isoform 1 precursor                                   |
| XYLTI_HUMAN  | Xylosyltransferase 1                                                         |
| ETBR2_HUMAN  | Endothelin B receptor-like protein 2 precursor                               |
| CSFR1_HUMAN  | Macrophage colony-stimulating factor 1 receptor precursor                    |
| PNOC_HUMAN   | Prepronociceptin preproprotein                                               |
| SPRC_HUMAN   | SPARC precursor                                                              |
| SORT_HUMAN   | Sortilin isoform 1 preproprotein                                             |
| ITM2B_HUMAN  | Integral membrane protein 2B                                                 |
| TYB4_HUMAN   | Thymosin beta-4                                                              |
| NCAM1_HUMAN  | Neural cell adhesion molecule 1 isoform 4 precursor                          |
| SYT11_HUMAN  | Synaptotagmin-11                                                             |
| SELPL_HUMAN  | P-selectin glycoprotein ligand 1 isoform 2                                   |
| PRR24_HUMAN  | Proline-rich protein 24                                                      |
| VGF_HUMAN    | Neurosecretory protein VGF precursor                                         |
| MGP_HUMAN    | Matrix Gla protein isoform 2 precursor                                       |
| CSTN3_HUMAN  | Calsyntenin-3 preproprotein                                                  |
| HPT_HUMAN    | Haptoglobin isoform 1 preproprotein                                          |
study, four of which have N-termini at the BACE cleavage site (Arg-167) in APLP1 (Figure 5 b). The peptides derived from APLP1 and APP may thus be used in parallel in clinical studies to monitor the activity of these secretases to investigate if similar patterns of peptides are affected in different disease or to monitor effects of pharmaceutical compounds that target a given enzyme.

CART. Another interesting finding is the identification of fragment 28–36 of cocaine- and amphetamine-regulated transcript (CART), covering part of the amino acid sequence of CART[1–39]. This peptide is involved in regulating many processes including body weight, reward and endocrine functions [40]. CART is together with NPY believed to regulate the leptin-mediated feeding response [41].

NPY. Neuropeptide Y is a highly abundant neuropeptide and a potent neuromodulator involved in several different processes, e.g., hunger, stress response, cardiovascular function, and circadian rhythms [42]. Three peptides were identified that span part of the NPY 1–36 sequence: NPY 1–20, 3–22, and 5–22, none of which have been previously reported in CSF. It is believed that the intact NPY 1–36 is the active peptide although it has not been shown in intact form in CSF.

MOG. From myelin oligodendrocyte glycoprotein (MOG) we identified six peptides spanning part of the extracellular region with a common cleavage site C-terminally to the amino acid at position 81. MOG is found on the surface of the myelin sheath and has an yet unclear role in multiple sclerosis where autoantibodies against the protein are found [43]. The levels of autoantibodies against MOG seem to be an indicator of disease intensity.

Granins. Peptides from the granin family have been discussed as CSF biomarkers for various diseases such as AD, multiple sclerosis, schizophrenia, and depression [44]. The granins (Chromogranin-A (CMGA), Secretogranin-1 (SCG1), Secretogranin-2 (SCG2), Secretogranin-3, 7B2, NESP22, proSAAS, and VGF) are involved in regulated delivery of several key factors in CNS such as neurotransmitters, hormones and growth factors. Peptides from Neurosecretory protein VGF have been associated with different brain disorders, such as VGF26–62 [45] with decreased levels in frontotemporal dementia; VGF 378–397 [46,47], with decreased levels in AD; VGF 23–62 [48], with increased levels in schizophrenia and in depression; and SCG2 529–566 [48], with decreased levels in depression. In our study three of the peptides (VGF 26–62, VGF 23–62, and SCG2 529–566) were found both as intact peptides and in truncated forms, while the third VGF peptide was only found as peptides exceeding the sequence length with 1–6 amino acids. In the case of SCG2 and CMGA, an alteration in three peptides is described as potential marker for multiple sclerosis, decreased SCG1 441–493 [49] and SCG1 306–365 [49] and increased CMGA 194–213 [50,51].

SCG1 441–493 has also been found decreased in frontotemporal dementia [45]. Although we did not identify any of SCG1 441–493, SCG1 306–365, or CMGA 194–213 as intact peptides, we identified several forms spanning parts of these sites (Figure 6).

Prion protein. Nine fragments of the prion protein were identified. The detected peptides are fragments created after the signal peptide has been removed from the protein with some starting at amino acid position 23 and others starting more C-terminally in the octapeptide repeat region which is associated to prion disease [32]. In CJD, which is characterized by spongiform degeneration and neuronal death leading to dementia, motor dysfunction, and eventually death, the prion protein plays a critical role. When the prion protein assumes an abnormal conformation it becomes very prone to aggregation, which starts an autocatalytic cascade that eventually produces neurotoxic species of the protein [53,54].

Conclusion
Our results show that LC-MALDI MS can be used for monitoring large numbers of endogenous CSF peptides in sample volumes relevant to clinical studies. Several of the identified peptides derive from proteins involved in physiological and pathological processes in the CNS. The CSF peptidome contains information about peptides spanning other parts of the proteins than are found using bottom-up proteomic workflows, and may thus be a complementary strategy for identifying biomarkers of disease. Supplementing the method described here with stable isotope labeling methods for quantification, such as the tandem mass tag (TMT) or the isobaric tags for relative and absolute quantitation (iTRAQ) approaches may be a viable strategy for identification of new biomarkers in CSN disorders.

Methods
Ethics statement
The study was approved by the regional ethics committee at the University of Gothenburg.

Materials
MALDI grade α-cyano-4-hydroxycinnamic acid (HCCA, part no. 201344) and mass calibrants (Peptide mass calibration standard II, part no. 222570) were purchased from Bruker Daltonics. Purified water was used for all solutions (Milli-Q Plus, Millipore), except for preparation of MALDI matrix solutions, which were prepared from bottled water (part no. 39253-1L-R) from Merck. MWCO filters were purchased from Millipore (Amicon Ultra 0.5 mL 30 K, part no. UFC503096). FA (98%, part no. 56302-10) was purchased from Sigma-Aldrich and utilized for preparation of MALDI matrix solutions.

Table 1. Cont.

| Entry name     | Protein name                      |
|----------------|-----------------------------------|
| HEG1_HUMAN     | Isoform 2 of Protein HEG homolog 1|
| CAD11_HUMAN    | Isoform 2 of Cadherin-11          |
| CCKN_HUMAN     | Cholecystokinin preproprotein     |
| B2MG_HUMAN     | Beta-2-microglobulin precursor    |
| NPY_HUMAN      | Pro-neuropeptide Y preproprotein  |
| CGRE1_HUMAN    | Cell growth regulator with EF hand domain protein 1 |
| ALBU_HUMAN     | Serum albumin preproprotein       |

doi:10.1371/journal.pone.0042555.t001

CSF Peptidomics by LC-MALDI MS
trifluoro-acetic acid (reagent grade, >98%, part no. T6508) from Sigma-Aldrich.

CSF samples

CSF samples collected by lumbar puncture from patients undergoing clinical evaluation were obtained from the Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital Mölndal, Sweden. To eliminate cells and other insoluble material, the CSF samples were centrifuged at 2,000 $\times$ 4°C for 10 min. Samples were selected from patients who did not display any clear signs of neurological disorder, with respect to cell counts, albumin CSF to serum ratio and signs of intrathecal immunoglobulin production. CSF was de-identified and pooled from 3 different patients to achieve sufficient volume. All samples were stored at -80°C pending analysis.

Figure 4. Comparison of the peptides identified in the current study to other published peptidomic and proteomic data. Only 23% of the peptides identified in the current study were part of the peptide set reported by Zougman et al. [14]. Comparison of the proteins represented by the endogenous peptides identified in the current study and in the study by Zougman et al. with the proteins identified in the CSF proteomic analysis by Schutzer et al. [7] reveals that both peptide sets have a high degree overlap with the proteomic set. doi:10.1371/journal.pone.0042555.g004

Figure 5. Identified endogenous peptides from (a) Amyloid beta A4 protein isoform h precursor (A4_HUMAN, commonly referred to as APP) and (b) Amyloid-like protein 1 isoform 1 (APLP1). The peptides identified from A4_HUMAN are all located within the $\beta$-amyloid peptide, starting at or in proximity of the N-terminus of the peptide, defined by the BACE cleavage site. Correspondingly, four of the peptides identified in APLP1 are generated by BACE cleavage C-terminally to Arg-567. doi:10.1371/journal.pone.0042555.g005
Sample preparation

The CSF pool was split into aliquots of 500 µl each. To the samples were added ACN (20%–40% (v/v)) or FA (5%–10% (v/v)) after which the samples were briefly vortexed and incubated for 20 minutes at room temperature. MWCO filters of 10, 30 and 50 kDa were washed with 0.5 ml H2O prior to use. The CSF samples were centrifuged through the filters according to the

Figure 6. Peptides identified from the Granin family. (a) Chromogranin- A (CMGA), (b) Secretogranin 1 (SCG1), (c) Secretogranin 2 (SCG2), (d) Neurosecretory protein VGF (VGF).

doi:10.1371/journal.pone.0042555.g006
manufacturer’s recommendations. The flow-through from the filters containing the peptide fraction was recovered and lyophilized. The lyophilized samples were stored at −80 °C pending analysis. To dissolve the samples, 20 μl of 0.5 M HCl, 1% TFA (v/v) was added and the samples were vortexed for 30 minutes.

**Liquid chromatography**

Peptides were loaded onto a trap column (Acclaim PepMap100 C18, 75 μm × 20 mm, LC Packings) and separated with a C18 column (Acclaim PepMap C18, 75 μm × 150 mm, LC packings) on an Ultimate 3000 nano-LC system ( Dionex). A sample volume of 20 μl was injected and a 150 minute gradient was used for peptide separation. The mobile phases used were A, 0.05% TFA (v/v) and B, 80% ACN (v/v), 0.05% TFA. A solenoid-valve liquid dispensing robot (Instrument2, M2 Automation) was connected to the nano-LC device and was used to dispense fraction from the nano-LC separation onto a 600 μm Anchor Chip 1536 MALDI sample plate (Bruker Daltonics). The effluent from the nano-LC was mixed with HCCA matrix solution (4 g/l, 70% ACN (v/v), 0.1% TFA (v/v)) in a T-junction proximally to the capillary end, and dispensed onto the target plate. Mass calibrants mixed with HCCA matrix solution (4 g/l in 70% ACN (v/v), 0.1% TFA (v/v)) were deposited in a pattern covering the MALDI target for near-neighbor external mass calibration.

**Mass spectrometry**

The fractionated samples were analyzed with a MALDI TOF/TOF (Ultraflextreme, Bruker Daltonics, Bremen) instrument operated in the positive ion mode. The analyzed mass range was 700–5,000 Da with deflection up to m/z 600. For MS analysis, 2,000 single shot spectra were accumulated from 10 random positions on each sample, irradiating each position with 200 laser pulses. From the MS analysis, compounds with S/N>15, were selected for MS/MS analysis. For MS/MS analysis 2,000 single shot spectra were recorded of the precursor ions and 4,000 of the fragment ions. The analyses of the MS spectra and selection of compounds for MS/MS analyses was performed using the WARP-LC software (Bruker Daltonics), which automatically executed the MS and MS/MS analysis.

**Bioinformatics**

All the acquired data were processed using the ProteinScape software (Bruker Daltonics). The MS/MS data were searched using the Mascot search engine (Matrix science) against the SwissProt sequence database with the Homo sapiens subset considering the following variable modifications: phosphorylation, amidation, deamidation, pyroglutamic acid, oxidation, acetylation, sulfation, and oxidized as well as reduced cysteines. The error tolerance for precursor ion masses was set to 15 ppm and for fragment ion masses, 0.6 Da. All included peptides in the search were at least 7 amino acids long. A lower peptide score threshold of 15 was used. Protein hits with at least one peptide with ion score >27 were retrieved. For these, all peptide matches were manually validated. The search results were compiled into a protein list using ProteinScape. All MS/MS spectra considered for protein identification were manually validated using the BioTools software (Bruker, Bremen, Germany) according to the following rules: a) prominent cleavage N-terminally to proline, b) b and y ion pairs, c) ion series continuity d) major peaks identified as b or y ions e) resemblance of fragment ion patterns in peptide hits that cover partially the same amino acid sequence in a protein, f) abundance of y/b ions according to position of basic amino acids in the sequence.

**Supporting Information**

Table S1 List of identified peptides from the analysis of the CSF peptidome using LC-MALDI MS/MS.

**Acknowledgments**

We would like to thank Bozena Zayer for technical support.

**Author Contributions**

Conceived and designed the experiments: MH JG. Performed the experiments: MH JG. Analyzed the data: MH JG EM NM HZ KB. Contributed reagents/materials/analysis tools: KB HZ. Wrote the paper: MH JG HZ NM KB.

**References**

1. Zhang J, Goodlett DR, Montine TJ (2005) Proteomic biomarker discovery in cerebrospinal fluid for neurodegenerative diseases. J Alzheimers Dis 8: 377–386.

2. Hokeføt T, Brobye B, Xu ZQ, Sergeyev V, Uibink R, et al. (2000) Neuropeptides—an overview. Neuropharmacology 39: 1337–1356.

3. Johansson CE, Duncan JA, 3rd, Klinge PM, Brinker T, Stopa EG, et al. (2008) Multiplicity of cerebrospinal fluid functions: New challenges in health and disease. Cerebrospinal Fluid Res 5: 10.

4. Harrington MG, Fonteh AN, Oborina E, Liao P, Cowan RP, et al. (2009) The fractionated samples were analyzed with a MALDI TOF/TOF (Ultraflextreme, Bruker Daltonics, Bremen) instrument operated in the positive ion mode. The analyzed mass range was 700–5,000 Da with deflection up to m/z 600. For MS analysis, 2,000 single shot spectra were accumulated from 10 random positions on each sample, irradiating each position with 200 laser pulses. From the MS analysis, compounds with S/N>15, were selected for MS/MS analysis. For MS/MS analysis 2,000 single shot spectra were recorded of the precursor ions and 4,000 of the fragment ions. The analyses of the MS spectra and selection of compounds for MS/MS analyses was performed using the WARP-LC software (Bruker Daltonics), which automatically executed the MS and MS/MS analysis.

5. Maccarrone G, Miflay D, Birg I, Rosenhagen M, Holsboer F, et al. (2004) Multiplicity of cerebrospinal fluid functions: New challenges in health and disease. Cerebrospinal Fluid Res 5: 10.

6. Maccarrone G, Miflay D, Birg I, Rosenhagen M, Holsboer F, et al. (2004) Mining the human cerebrospinal fluid proteome by immunodepletion and shotgun mass spectrometry. Electrophoresis 25: 2402–2412.

7. Pan X, Zhu D, Quinn JF, Peskind ER, Montine TJ, et al. (2007) A combined dataset of human cerebrospinal fluid proteins identified by multi-dimensional chromatography and tandem mass spectrometry. Proteomics 7: 469–473.

8. Schütze SE, Liu T, Naitoh BH, Angle TE, Schepmoes AA, et al. (2010) Establishing the proteome of normal human cerebrospinal fluid. PLoS One 5: e10980.

9. Sickmann A, Dormeyer W, Wörtelkamp S, Woitalla D, Kuhn W, et al. (2000) Identification of proteins from human cerebrospinal fluid, separated by two-dimensional polyacrylamide gel electrophoresis. Electrophoresis 21: 2721–2720.

10. Thouvenot E, Urbach S, Dantec C, Poncet J, Sevento M, et al. (2008) Enhanced detection of CNS cell secreteome in plasma protein-depleted cerebrospinal fluid. J Proteome Res 7: 4409–4421.

11. Wernery BR, Lovell MA, Lynn BC (2004) Proteomic analysis of human ventricular cerebrospinal fluid from neurologically normal, elderly subjects using two-dimensional LC-MS/MS. J Proteome Res 3: 97–103.

12. Xu J, Chen J, Peskind ER, Jin J, Eng J, et al. (2006) Characterization of proteome of human cerebrospinal fluid. Int Rev Neurobiol 73: 29–98.

13. Yuan X, Desiderio DM (2005) Proteomics analysis of prefractionated human lumbar cerebrospinal fluid. Proteomics 5: 544–550.

14. Zhang J, Goodlett DR, Peskind ER, Quinn JF, Zhou Y, et al. (2005) Quantitative proteomic analysis of age-related changes in human cerebrospinal fluid. Neurobiol Aging 26: 207–227.

15. Zougman A, Pich B, Podlecjonik A, Kiehnopf M, Schnabel C, et al. (2008) Integrated analysis of the cerebrospinal fluid peptidome and proteome. J Proteome Res 7: 386–399.

16. Zougman A, Pich B, Podlecjonik A, Kiehnopf M, Schnabel C, et al. (2008) Integrated analysis of the cerebrospinal fluid peptidome and proteome. J Proteome Res 7: 386–399.

17. Zougman A, Pich B, Podlecjonik A, Kiehnopf M, Schnabel C, et al. (2008) Integrated analysis of the cerebrospinal fluid peptidome and proteome. J Proteome Res 7: 386–399.
18. Liu Z, Petricoin EF (2006) Serum peptideome for cancer detection: spinning biologic trash into diagnostic gold. J Clin Invest 116: 26–30.

19. Villanueva J, Martorell AJ, Lawlor K, Philip J, Fleisher M, et al. (2006) Serum peptide patterns that distinguish metastatic thyroid carcinoma from cancer-free controls are unbiased by gender and age. Mol Cell Proteomics 5: 1040–1052.

20. Villanueva J, Shaffer DR, Philip J, Chaparro CA, Ejdemand-Beomage H, et al. (2006) Differential exoprotope activities confer tumor-specific serum peptide patterns. J Clin Invest 116: 271–284.

21. Lopez MF, Mikulski A, Kuzhalz S, Bennett DA, Kelly J, et al. (2005) High-resolution serum proteomic profiling of Alzheimer disease samples reveals disease-specific, carrier-protein-bound mass signatures. Clin Chem 51: 1246–1254.

22. Jahn H, Wintke S, Zurbig P, Raedler TJ, Arb S, et al. (2011) Peptide fingerprinting of Alzheimer’s disease in cerebrospinal fluid: identification and prospective evaluation of new synaptic biomarkers. PLoS One 6: e26540.

23. Blennow K, Fredman P, Wallin A, Gottfries CG, Karlsson I, et al. (1993) Protein analysis in cerebrospinal fluid: II. Reference values derived from healthy individuals 18–88 years of age. Eur Neurol 33: 129–133.

24. Jurado R, Walker HK (1990) Cerebrospinal Fluid.

25. Huhmer AF, Biringer RG, Amato H, Fonten AN, Harrington MG (2006) Protein analysis in human cerebrospinal fluid: Physiological aspects, current progress and future challenges. Dis Markers 22: 3–26.

26. Shores KS, Knapp DR (2007) Assessment approach for evaluating high abundance protein depletion methods for cerebrospinal fluid (CSF) proteomic analysis. J Proteome Res 6: 3739–3751.

27. Huang H, Staayk T, Morandell S, Mogg M, Schreiber M, et al. (2005) Enrichment of low-abundance serum proteins by albumin/immunoglobulin G immunoaffinity depletion under partly denaturing conditions. Electrophoresis 26: 2843–2849.

28. Tirumalai RS, Chan KC, Prieto DA, Issaq HJ, Conrads TP, et al. (2003) Characterization of the low molecular weight human serum proteome. Mol Cell Proteomics 2: 1099–1109.

29. Yu W, Vathy JE, Hubers MC, Martin SA (1993) Identification of the facile gas-phase cleavage of the Asp-Pro and Asp-Xxx peptide bonds in matrix-assisted laser desorption time-of-flight mass spectrometry. Anal Chem 65: 3015–3023.

30. Gu CG, Somogyi A, Wysocki VH, Medzihradszky KF (1999) Fragmentation of protonated oligopeptides XLDV/LQ (N = L, H, K or R) by surface induced dissociation: additional evidence for the ‘mobile proton’ model. Analytica Chimica Acta 397: 247–256.

31. Vizzaino JA, Cote R, Reisinger F, Barnes H, Foster JM, et al. (2010) The Proteomics Identifications database: 2010 update. Nuclear Acids Res 38: D736–742.

32. Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimer’s disease. Lancet 368: 387–403.

33. Blennow K, Hampel H, Weiner M, Zetterberg H (2010) Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 6: 131–144.

34. Portelius E, Westman-Brinkmalm A, Zetterberg H, Blennow K (2006) Determination of beta-amyloid peptide signatures in cerebrospinal fluid using immuno precipitation-mass spectrometry. J Proteome Res 5: 1010–1016.

35. Andreasson U, Portelius E, Andersson ME, Blennow K, Zetterberg H (2007) Aspects of beta-amyloid as a biomarker for Alzheimer’s disease. Biomark Med 1: 59–78.

36. Takeda K, Araki W, Akiyama H, Tahira T (2004) Amino-truncated amyloid beta-peptide (Abeta35-40/42) produced from caspase-cleaved amyloid precursor protein is deposited in Alzheimer’s disease brain. FASEB J 18: 1755–1757.

37. Portelius E, Price E, Brinkman K, Suterer M, Olson M, et al. (2011) A novel pathway for amyloid precursor protein processing. Neurobiol Aging 32: 1090–1098.

38. Mattsson N, Rajendran L, Zetterberg H, Gustavsson M, Andreasson U, et al. (2012) BACE1 Inhibition Induces a Specific Cerebrospinal Fluid beta-Amyloid Pattern That Identifies Drug Effects in the Central Nervous System. PLoS One 7: e11094.

39. Yamagata K, Okochi M, Tagami S, Nakayama T, Koedama TS, et al. (2009) The 28-amino acid form of an APP-like derived Abeta-like peptide is a surrogate marker for Abeta42 production in the central nervous system. EMBO Mol Med 1: 223–235.

40. Rogge G, Jones D, Hubert GW, Lin Y, Kuhr MJ (2008) CART peptides: regulators of body weight, reward and other functions. Nat Rev Neurosci 9: 747–758.

41. Kristensen P, Judge ME, Thim L, Ribe E, Christiansen KN, et al. (1998) Hypothalamic CART is a new anorectic peptide regulated by leptin. Nature 393: 72–76.

42. Benaroch EE (2009) Neuropeptide Y: its multiple effects in the CNS and potential clinical significance. Neurology 72: 1016–1020.

43. Berger T, Reinull M (2006) Immunopathogenic and clinical relevance of antibodies against myelin oligodendrocyte glycoprotein (MOG) in Multiple Sclerosis. J Neural Transm Suppl. 331–360.

44. Bartolomucci A, Possenti R, Mahata SK, Fischer-Colbrie R, Lob YP, et al. (2011) The extended granin family: structure, function, and biomedical implications. Endoc Rev 32: 755–797.

45. Ruetschi U, Zetterberg H, Podust VN, Gottfries J, Li S, et al. (2005) Identification of CSF biomarkers for frontotemporal dementia using SELDI-TOF. Exp Neurol 196: 273–281.

46. Carrette O, Demalte I, Scherl A, Yalkinoglu O, Corthals G, et al. (2003) A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer’s disease. Proteomics 3: 1486–1494.

47. Simonsen AH, McGuire J, Podust VN, Hagnelius NO, Nilsson TK, et al. (2007) A novel panel of cerebrospinal fluid biomarkers for the differential diagnosis of Alzheimer’s disease versus normal aging and frontotemporal dementia. Dement Geriatr Cogn Disord 24: 434–440.

48. Huang JT, Leseske FM, Ostrzy D, Wang L, Harris N, et al. (2006) Disease biomarkers in cerebrospinal fluid of patients with first-onset psychosis. PLoS Med 3: e428.

49. Mattsson N, Ruetschi U, Podust VN, Stridsberg M, Li S, et al. (2007) Cerebrospinal fluid concentrations of peptides derived from chromogranin B and secretogranin II are decreased in multiple sclerosis. J Neurochem 103: 1932–1939.

50. Stoop MP, Dekker LJ, Titulaer MK, Burgers PC, Sillevis Smit PA, et al. (2008) Multiple sclerosis-related proteins identified in cerebrospinal fluid by advanced mass spectrometry. Proteomics 8: 1576–1585.

51. Stoop MP, Dekker LJ, Titulaer MK, Lammers RJ, Burgers PC, et al. (2009) Quantitative matrix-assisted laser desorption ionization-fourier transform ion cyclotron resonance (MALDI-FT-ICR) peptide profiling and identification of multiple-sclerosis-related proteins. J Proteome Res 8: 1404–1414.

52. Capellari S, Strambelli R, Savioni D, Kretschmar H, Parich P (2011) Genetic Creutzfeldt-Jakob disease and fatal familial insomnia: insights into phenotypic variability and disease pathogenesis. Acta Neuropathol 121: 21–37.

53. Flechsig J, Weissmann C (2004) The role of PrP in health and disease. Curr Mol Med 4: 337–353.

54. Sandberg MK, Al-Doujaily H, Shaps B, Clarke AR, Collinge J (2011) Prion propagation and toxicity in vivo occur in two distinct mechanistic phases. Nature 470: 540–542.